Does magnesium help memory and brain fog?

Nobody knows yet. A 2024 systematic review found only 3 randomized trials of magnesium supplements and cognition, and judged them insufficient to draw conclusions. The trials we found are small and short, and most tested one branded form, magnesium L-threonate. In the largest, 100 adults aged 18 to 45 who slept poorly scored better on an overall cognition test after 6 weeks than on placebo, with a p-value of 0.043. We found no trial that measured brain fog.

Unsettled. The evidence is too thin to answer either way. The randomized trials are few, small and short, most tested one branded product, one was developed by the trial sponsor, and none lasted longer than 12 weeks.

Dementia risk and magnesium in population studies

Observational data

Every row is a hazard ratio from observational data, which cannot show cause. Serum magnesium reflects kidney function and illness as much as diet. The Rotterdam rows may overlap with the pooled review. Sources: cards ev-mgme-02, ev-mgme-09, ev-mgme-10, ev-mgme-11 and ev-mgme-12 below.

What the trials found

The 6-week trial in 100 young adults with poor sleep used 2 g a day of a magnesium L-threonate product, which supplied 145 mg of elemental magnesium. The overall cognition score improved more than on placebo, mostly in working and episodic memory. It is one trial of a branded product, the main result sits just under the usual cut-off for significance, and the people were chosen for poor sleep rather than poor memory.

In a 12-week trial of 44 adults aged 50 to 70 with cognitive impairment, a magnesium L-threonate product improved an overall cognition score against placebo, with an effect size (Cohen's d) of 0.91. That is a large effect in a very small trial, and the product was developed by the trial sponsor.

A 30-day trial of 109 healthy Chinese adults tested a formula of magnesium L-threonate with phosphatidylserine and vitamins C and D. Memory test scores improved over placebo on all five subtests, but the abstract gives no size for the change and the effect cannot be put down to the magnesium.

In 40 outpatients with depression taking fluoxetine, adding 350 mg of magnesium a day for 6 weeks raised memory scores to 3.85 against 2.70 with fluoxetine alone. There was no placebo and no blinding was reported, and recovery from depression improves memory by itself. None of the sources here reports on the safety of magnesium taken alongside antidepressants, and that gap is not evidence of safety.

Laboratory work in rats is the starting point for the threonate trials. In the study we cite, magnesium L-threonate did not improve how well the rats kept a fear memory. Animal data are not evidence in people.

The population studies

Observational data point both ways at once. The 2024 review pooled cohorts that measured magnesium in blood and found the lowest dementia risk around 0.85 mmol/L. People below 0.75 had a hazard ratio of 1.43 and people above 0.95 had 1.30. The Rotterdam Study of 9,569 adults saw the same U shape over a median of 7.8 years, about 30% more dementia at both ends. In the ARIC cohort of 12,040 adults, the lowest midlife serum magnesium was linked with 24% more dementia over 24 years.

Diet studies are patchier. In 6,473 older US women, only the middle fifth of magnesium intake had a lower risk of mild cognitive impairment or dementia, a hazard ratio of 0.69 against the lowest. In a Japanese cohort of 13,032 adults, men with the lowest intake had a higher dementia risk, and women did not. All of these figures are relative, and none of the studies we found gives an absolute risk. None can show that magnesium is the cause.

Who should be careful

Not for everyone. If your kidneys do not work well, magnesium supplements can build up. The NIH Office of Dietary Supplements warns that the risk of magnesium toxicity rises with impaired kidney function or kidney failure. That is relevant to older adults, the group most interested in memory supplements.

The upper limit for supplemental magnesium is 350 mg a day for adults and 65 to 350 mg for children and teens, depending on age. The threonate trial supplied 145 mg, and the depression trial used 350 mg, right at the limit. In the 6-week threonate trial, side effects judged related to treatment were about as common on the product, 10%, as on placebo, 8%. Magnesium carbonate, chloride, gluconate and oxide are the forms most often reported to cause diarrhea. We found no comparison of threonate against these. Magnesium can interact with oral bisphosphonates and with tetracycline and quinolone antibiotics.

The cohort data add one more reason not to push blood magnesium up for its own sake. High serum magnesium was linked with more dementia as well as low, although that link is observational and may reflect kidney disease.

What expert bodies say

We found no position from any health agency on magnesium for memory, cognition or brain fog. The NIH Office of Dietary Supplements statements used here cover the upper limit, kidney function, drug interactions and diarrhea.

How we searched

Searched: a local copy of PubMed, on 7 October 2026. The broadest query paired magnesium with memory, cognition, dementia, brain fog, cognitive decline or Alzheimer's (189 hits, top 40 screened). Most were about intravenous magnesium sulfate in surgery or pregnancy, which is a drug use and off topic. Narrower queries covered magnesium L-threonate (6 and 3 hits) and serum or dietary magnesium with dementia in cohorts (11 hits).

Also searched: the web for 2025 and 2026 meta-analyses and trials (none new beyond the 2024 review), Europe PMC, the NIH Office of Dietary Supplements fact sheet and Retraction Watch for every cited paper (none retracted). No trial or review in the corpus or on the web used brain fog as an outcome.

Included: one systematic review with a meta-analysis of cohorts, four randomized trials, four cohort studies, one animal study and the NIH fact sheet. Seventeen cards in total: 1 at level A, 6 at B, 5 at C, 1 at D and 4 at E.

Excluded: trials of magnesium valproate, which is a drug, trials of intravenous magnesium sulfate for brain protection in surgery or pregnancy, a case-control study, a cross-sectional brain scan study, a study of laxative users and a general micronutrient consensus.

What we read: abstracts, each quotation checked against the abstract text, and the methods and safety sections of the 6-week threonate trial in full text.

What we could not get: the full text of the 2024 review, so the details of its trials come from the abstract only. Funding and conflict-of-interest statements for two of the threonate trials. A repeat of one Europe PMC search that failed.

What would change this answer

An independent, adequately powered randomized trial of magnesium in any form, lasting six months or more, in older adults with low magnesium, with memory as the main outcome. We found none registered.
A trial that tests brain fog or everyday memory complaints directly, which no study we found has done.
Head-to-head trials of threonate against cheaper forms at the same elemental dose, to show whether the branded form matters.

The rest of the nutrient, in one place. Magnesium: widely under-eaten, and widely over-promised → What it does, how much you need, who runs short, and what too much does, with the evidence level shown on every line.

The full guide

Magnesium: widely under-eaten, and widely over-promised

The same question for other foods (memory)

Does vitamin B12 help memory and brain fog?

Sources

ev-mgme-01 · Meta-analysis or systematic review · systematic review and meta-analysis of RCTs and cohort studies (PROSPERO CRD42023423663) · n = 3 RCTs and 12 cohorts
Evidence from the limited number of RCTs was insufficient to draw conclusions on the effects of Mg supplements.
Who: adults in RCTs and cohort studies of magnesium (supplements, diet, blood levels) and cognitive outcomes, searched to May 2024
Effect: RCT evidence insufficient; no pooled effect of supplements
Certainty: The main unknown: no adequately sized RCT on memory in the general population.
Adv Nutr, 2024 · checked 2026-10-07 · we read the abstract
ev-mgme-02 · Observational data · meta-analysis of prospective cohort studies within a systematic review · n = 12 cohorts
This nonlinear association was detected in meta-regression (Pquadratic = 0.003) and in meta-analysis based on the reference interval of serum Mg (0.75-0.95 mmol/L) [<0.75 compared with 0.85 mmol/L: pooled hazard ratio (HR) = 1.43; 95% confidence interval (CI) = 1.05, 1.93; >0.95 compared with 0.85 mmol/L: pooled HR = 1.30; 95% CI = 1.03, 1.64].
Who: adults in prospective cohort studies with serum magnesium measured
Effect: serum Mg below 0.75 vs 0.85 mmol/L: HR 1.43 (95% CI 1.05 to 1.93); above 0.95 vs 0.85: HR 1.30 (1.03 to 1.64)
Certainty: Observational; serum magnesium reflects kidney function and illness as much as intake.
Adv Nutr, 2024 · checked 2026-10-07 · we read the abstract
ev-mgme-03 · Randomized controlled trial(s) · randomized double-blind placebo-controlled parallel trial, 2 g/day Magtein for 6 weeks · n = 100
Compared to the placebo, Magtein® was associated with greater improvements in overall cognitive performance as measured by the NIH Total Cognition Composite (p = 0.043), with larger treatment effects on working and episodic memory.
Who: adults aged 18 to 45 with self-reported dissatisfied sleep
Effect: NIH Total Cognition Composite better than placebo (p=0.043); larger effects on working and episodic memory
Certainty: Single trial of a branded product; p just under 0.05 for the primary composite; population selected for poor sleep.
Front Nutr, 2025 · checked 2026-10-07 · we read the abstract
ev-mgme-04 · Randomized controlled trial(s) · randomized double-blind placebo-controlled parallel trial, Methods · n = 100
Participants took one capsule in the morning and one in the evening (2 h before bedtime, 1 g Magtein® per capsule) with or without food, with the active intervention delivering 2 g of Magtein® (145 mg of elemental magnesium) daily for 6 weeks.
Who: adults aged 18 to 45 with self-reported dissatisfied sleep
Effect: 2 g Magtein = 145 mg elemental magnesium per day, split morning and evening
Certainty: Well under the 350 mg UL for supplemental magnesium.
Front Nutr, 2025 · checked 2026-10-07 · we read the fulltext
ev-mgme-05 · Randomized controlled trial(s) · randomized double-blind placebo-controlled parallel trial, safety results · n = 100
In the placebo group, 8.0% (n = 4) of participants experienced a treatment-related adverse event, and in the Magtein® group, 10% (n = 5) of participants experienced a treatment-related adverse event.
Who: adults aged 18 to 45 with self-reported dissatisfied sleep
Effect: treatment-related adverse events 10% (5) Magtein vs 8.0% (4) placebo; no significant difference
Certainty: Six weeks only; small numbers.
Front Nutr, 2025 · checked 2026-10-07 · we read the fulltext
ev-mgme-06 · Randomized controlled trial(s) · randomized double-blind placebo-controlled trial, 2 g/day Magtein PS for 30 days · n = 109
Subjects receiving Magtein®PS showed significant improvements over the control group in all five subcategories of "The Clinical Memory Test" as well as the overall memory quotient scores.
Who: healthy Chinese adults aged 18 to 65
Effect: improvements in all five subtests of the Clinical Memory Test and the memory quotient; size not given in the abstract
Certainty: Multi-ingredient formula, so the effect cannot be assigned to magnesium; no effect size in the abstract.
Nutrients, 2022 · checked 2026-10-07 · we read the abstract
ev-mgme-07 · Randomized controlled trial(s) · randomized double-blind placebo-controlled parallel trial, MMFS-01 for 12 weeks · n = 44
With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p = 0.003; Cohen's d = 0.91).
Who: older adults aged 50 to 70 with cognitive impairment
Effect: overall cognitive ability composite p=0.003, Cohen's d 0.91 versus placebo
Certainty: Small; product developed by the trial sponsor; sleep and anxiety effects lost to placebo response.
Journal of Alzheimer's Disease, 2016, 49(4):971-90, Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults · checked 2026-10-07 · we read the abstract
ev-mgme-08 · Randomized controlled trial(s) · randomized controlled trial, fluoxetine plus 350 mg/day oral magnesium vs fluoxetine alone, 6 weeks · n = 40
At week 6, scores were significantly higher in the treatment group in the domains of attention (4.05 vs 3.10, p = 0.002), memory (3.85 vs 2.70, p < 0.001), and orientation (5.75 vs 5.05, p < 0.001).
Who: outpatients aged 18 to 50 with depression on fluoxetine, Indonesia
Effect: MoCA-Ina memory domain 3.85 vs 2.70 (p<0.001); attention 4.05 vs 3.10 (p=0.002) at week 6
Certainty: No placebo and no blinding reported; depression recovery itself improves cognition.
East Asian Arch Psychiatry, 2026 · checked 2026-10-07 · we read the abstract
ev-mgme-09 · Observational data · prospective population-based cohort · n = 9569
Both low serum magnesium levels (≤0.79 mmol/L) and high serum magnesium levels (≥0.90 mmol/L) were associated with an increased risk of dementia (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.02-1.69, and HR 1.30, 95% CI 1.02-1.67, respectively).
Who: adults free of dementia at baseline, Rotterdam Study, mean age 64.9
Effect: serum Mg 0.79 mmol/L or less: HR 1.32 (95% CI 1.02 to 1.69); 0.90 mmol/L or more: HR 1.30 (1.02 to 1.67)
Certainty: Observational; adjusted for kidney function and diuretics.
Neurology, 2017 · checked 2026-10-07 · we read the abstract
ev-mgme-10 · Observational data · prospective cohort · n = 12040
The lowest quintile of serum magnesium was associated with a 24% higher rate of incident dementia compared to those in the highest quintile of magnesium (HR, 1.24; 95% CI, 1.07, 1.44).
Who: US middle-aged adults presumed free of dementia, ARIC study
Effect: lowest vs highest quintile of serum Mg: HR 1.24 (95% CI 1.07 to 1.44) for dementia
Certainty: Single serum measure in midlife; observational.
Nutrients, 2020 · checked 2026-10-07 · we read the abstract
ev-mgme-11 · Observational data · prospective cohort · n = 6473
Participants in Q3 had a significantly lower risk of MCI/PD (HR 0.69, 95% CI 0.53 to 0.91) and MCI (HR 0.63, 95% CI 0.45 to 0.87) after multivariate adjustments.
Who: postmenopausal women aged 65 to 79 without dementia, Women's Health Initiative Memory Study
Effect: Q3 vs Q1 of total Mg intake: HR 0.69 (95% CI 0.53 to 0.91) for MCI/probable dementia; HR 0.63 (0.45 to 0.87) for MCI; non-linear
Certainty: Only the middle quintile was significant; non-linear; food frequency questionnaire.
BMJ Open, 2019 · checked 2026-10-07 · we read the abstract
ev-mgme-12 · Observational data · prospective cohort · n = 13032
Lower quartiles of energy-adjusted Mg intake were associated with a higher risk of dementia (P for trend = 0.0410) in males, with the lowest quartile (Q1) having an elevated risk of dementia (HR = 1.73, 95% CI:1.07-2.83) compared to the highest quartile (Q4, reference); however, this association was not found in females.
Who: community-dwelling Japanese adults aged 40 to 74
Effect: men, lowest vs highest quartile of energy-adjusted Mg intake: HR 1.73 (95% CI 1.07 to 2.83); no association in women
Certainty: Attenuated after stratifying by disease history; possible reverse causation.
J Nutr Sci, 2026 · checked 2026-10-07 · we read the abstract
ev-mgme-13 · Laboratory or animal data · animal experiment · n = —
MgT treatment did not enhance the retention of contextual-fear memory.
Who: male Sprague-Dawley rats
Effect: no gain in contextual-fear memory retention
Certainty: Animal data; the basis for the threonate trials.
Behav Pharmacol, 2013 · checked 2026-10-07 · we read the abstract
ev-mgme-14 · Position of an expert body · agency fact sheet · n = —
The Tolerable Upper Intake Level for supplemental magnesium is 350 mg for adults, and it ranges from 65 to 350 mg for children and adolescents, depending on age.
Who: adults; children and adolescents
Effect: UL for supplemental magnesium 350 mg/day (adults); food magnesium not counted
Certainty: Threonate trials used 145 mg elemental; the depression trial used 350 mg.
NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
ev-mgme-15 · Position of an expert body · agency fact sheet · n = —
The risk of magnesium toxicity increases with impaired renal function or kidney failure because the ability to remove excess magnesium is reduced or lost
Who: people with impaired renal function or kidney failure
Effect: higher risk of magnesium toxicity
Certainty: Relevant to older adults, the group most interested in memory supplements.
NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
ev-mgme-16 · Position of an expert body · agency fact sheet · n = —
Magnesium may interact with certain medications, such as oral bisphosphonates, tetracyclines, and quinolone antibiotics.
Who: people taking oral bisphosphonates, tetracyclines or quinolones
Effect: drug interactions
Certainty: Doses should be spaced from these drugs.
NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section
ev-mgme-17 · Position of an expert body · agency fact sheet · n = —
The forms of magnesium that are most commonly reported to cause diarrhea include magnesium carbonate, chloride, gluconate, and oxide
Who: people taking magnesium supplements or medicines
Effect: diarrhea, nausea, cramping at high doses
Certainty: Threonate is not on this list; no head-to-head tolerability data found.
NIH Office of Dietary Supplements, Magnesium fact sheet for health professionals · checked 2026-10-07 · we read the section

How this page was made. Evidence was extracted from primary sources into cards, every number was re-checked against the source, and the text was written from those cards. Bioma Learn has no human medical reviewer at this time, and we say so rather than invent one. Methodology. This is information, not medical advice.